PCM
LXRX icon

Penserra Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Penserra Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-910
Closed -$1K – 1086
2020
Q3 		$1K Buy
+910
New +$1.62K ﹤0.01% 923

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Penserra Capital Management's LXRX Position: Q4 2020 in Review

Penserra Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2020, closing a stake of 910 shares — an estimated $1K sold.

Penserra Capital Management first reported a position in LXRX in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 106 funds tracked by Wall St. Rank hold LXRX as of Q4 2020.

  • Penserra Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Penserra Capital Management sold 910 Lexicon Pharmaceuticals shares in Q4 2020, an estimated $1K.
  • Penserra Capital Management first reported a position in Lexicon Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Penserra Capital Management's Lexicon Pharmaceuticals position peaked at $1K in Q3 2020.
  • 106 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2020.

Based on Penserra Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.